Prot #ACCRU SC-1601: A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation

Project: Research project

Project Details

Effective start/end date9/1/209/1/23


  • Mayo Clinic (Prot #ACCRU SC-1601)
  • Bristol-Myers Squibb Company (Prot #ACCRU SC-1601)